Dynamics of lipid spectrum and markers of inflammation in the patients receiving atorvastatin in hypertensive patients combined with chronic obstructive pulmonary disease
Keywords:
arterial hypertension, chronic obstructive pulmonary disease, dyslipidemia, inflammatory markers, atorvastatinAbstract
Objective. To evaluate the performance of lipid profile and markers of inflammation in the dynamics of patients receiving atorvastatin in patients with arterial hypertension and chronic obstructive pulmonary disease.
Material and methods. The study involved 158 patients aged 18–65 years, of which 53 patients with hypertension, 51 patients with COPD, 54 patients with a combination of hypertension and COPD control group consisted of 25 patients without hypertension and COPD.
Special methods of research: – Determination of carbohydrate, protein and lipid metabolism, the concentration of cytokines (IL – 1β and TNF – alpha), blood levels of adipokines (free leptin, resistin, adiponectin), assessment of body composition by bioimpedance component. Patients with comorbid over hypertension and COPD received standard therapy, as well as within six months of atorvastatin 40 mg per day and then re-lipid status were evaluated and markers of inflammation.
Results. Initially, the patients with a combination of hypertension and COPD revealed an increase in fat mass, total and extracellular fluid. Just decreased lean (lean) mass. Revealed atherogenic dyslipidemia, deficiency of protein fractions, high content of negative adipokines – leptin and resistin, adiponectin levels decline. Just found an increased concentration of inflammatory mediators IL – 1β and TNF – α. The dynamics on the background of atorvastatin therapy showed a significant improvement in lipid profile and inflammatory mediators.
Conclusions. For patients with comorbid hypertension and course of COPD is characterized by marked changes in body composition, dyslipidemia, disorders of protein metabolism and adipotsitokinin status. The therapy with atorvastatin 40 mg per day showed a significant improvement in lipid profile, as well as a reduction in the concentration of markers of systemic inflammation
